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Abstract. Artemisinin combination therapies (ACTs) have recently been adopted as first-line therapy for Plasmo-
dium falciparum infections in most malaria-endemic countries. In this study, we estimated the association between
artesunate-mefloquine therapy failure and genetic changes in the putative transporter, pfmdr1. Blood samples were
acquired from 80 patients enrolled in an 2004 in vivo efficacy study in Pailin, Cambodia, and genotyped for pfmdr1 copy
number and haplotype. Having parasites with three or more copies of pfmdr1 before treatment was strongly associated
with recrudescence (hazard ratio [HR]  8.30; 95% CI: 2.60–26.43). This relationship was maintained when controlling
for initial parasite density and hematocrit (HR  7.91; 95% CI: 2.38–26.29). Artesunate-mefloquine treatment selected
for increased pfmdr1 copy number, because isolates from recurrent episodes had higher copy numbers than the paired
enrollment samples (Wilcoxon rank test, P  0.040). pfmdr1 copy number should be evaluated further as a surveillance
tool for artesunate-mefloquine resistance in Cambodia.
INTRODUCTION
One of the challenges in the treatment and control of fal-
ciparum malaria is drug resistance. The Thai–Cambodian
border, in particular, is a hotspot for the emergence of anti-
malarial resistance: some of the earliest reports of chloro-
quine and pyrimethamine resistance came from this area.1 In
addition, high failure rates of mefloquine monotherapy were
documented in the 1990s.2
Artemisinin combination therapy (ACT) has been pro-
moted as an effective strategy to combat the emergence and
spread of resistance.3 Currently, 38 countries have adopted
ACT as first-line regimens for the treatment of malaria.4
However, a recent in vivo efficacy study on Thailand’s border
with Cambodia reported an artesunate-mefloquine 28-day
cure rate of 78.6%.5 In addition, an in vivo study on the
Cambodian side of the border documented a 28-day cure rate
of 85.7% in 2002.6 These studies suggest declining suscepti-
bility to the artesunate-mefloquine combination in this sub-
region. However, it is not yet known whether these reported
ACT failures are caused by true parasite resistance.
Because antimalarial resistance can emerge quickly, sur-
veillance is a key element to a successful malaria control pro-
gram.7,8 While the gold standard for monitoring drug efficacy
is the in vivo trial, molecular markers could provide an inex-
pensive complementary tool. Before they can be used in a
particular area, the relationship between specific molecular
markers and in vivo resistance must be established.
One possible molecular marker is Plasmodium falciparum
multidrug resistance gene-1 (pfmdr1). Single nucleotide poly-
morphisms (SNPs) and gene copy number have previously
been associated with in vitro resistance to a wide array of
antimalarials, including chloroquine, lumefantrine, quinine,
halofantrine, mefloquine, and artesunate.9–16 However, in
vitro and in vivo resistance are not always correlated.13 The
purpose of this study was to determine whether pfmdr1 ge-
netic changes are associated with in vivo evidence of resis-
tance to artesunate-mefloquine in Cambodia.
MATERIALS AND METHODS
Clinical study. We executed this clinical study at Pailin,
Cambodia, between June and September of 2004 in conjunc-
tion with the annual monitoring of antimalarial drug efficacy
in Cambodia carried out by the National Malaria Control
Program. The details of this study have been previously pub-
lished and were based on the WHO 2003 protocol for low
transmission areas.6,17 Briefly, the eligibility criteria for this
study were age > 6 years, having uncomplicated P. falciparum
malaria with no other Plasmodium species present, having an
initial parasite density  100,000 asexual parasites/L, having
a measured axillary temperature  37.5°C, providing in-
formed consent (by parent or guardian, when appropriate),
and willing to return for follow-up. In total, 25 children and 56
adults were enrolled.
At enrollment, a brief clinical exam was performed, and a
questionnaire was administered. Approximately 2 mL of ve-
nous blood was collected and frozen. Subjects were treated
according to the national policy: they were given 25 mg/kg
mefloquine and 12 mg/kg artesunate over 3 days (Days 0–2).
The mefloquine was divided into two equal doses and given in
the morning and evening on the day of enrollment (Day 0).
The daily 4-mg/kg dose of artesunate was divided into two
doses on Day 0 and given in one dose on the next 2 days.
Subjects stayed at the clinic for 3–4 days (depending on when
the parasites cleared) and had follow-up visits at 7, 14, 21, 28,
35, and 42 days after the date of enrollment. People who did
not return on their own were actively sought out. At these
follow-up visits, temperature was measured, and thick blood
smears were used to screen for peripheral parasitemia. In
instances of reoccurrence of parasitemia, an additional blood
sample was acquired and stored on 3M Whatman filter paper
(Whatman, Middlesex, UK).
Genotyping. DNA was extracted using the Qiamp DNA
mini kit (Qiagen, Hilden, Germany). Samples taken at enroll-
ment (Day 0), Day 1, and recurrence of parasitemia were
used to distinguish between recrudescence and reinfection.
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The number of variants in three polymorphic genes (msp1,
msp2, and glurp) was measured using size fractionization and
ethidium bromide staining.18,19 The number of unique bands
was determined visually and confirmed by measuring band
size using Quantity One software on Gel Doc 2000 (Bio-Rad,
Hercules, CA). If the recurrence specimen contained one or
more of the variants seen in the enrollment or Day 1 speci-
men, the infection was classified as a recrudescence. If the
recurrence specimen contained no variants present in the en-
rollment or Day 1 sample, it was classified as a reinfection.
Enrollment and recurrence samples were genotyped at
pfmdr1 codons 86, 184, 1,034, and 1,042 using real-time poly-
merase chain reaction (PCR). A previously published proto-
col was followed, except that the concentration of probes was
changed to 200 nmol/L.20
Pfmdr1 copy number was assessed for all samples using a
modification of two previous assays.11,21 The primers and a
FAM-TAMRA (6-carboxyfluorescein 6-carboxy-tetra-
methylrhodamine) probe specific to a conserved region of
pfmdr1 and the primers and a VIC-TAMRA (chemical struc-
ture not released by Applied Biosystems) probe specific to
-tubulin were multiplexed so that both genes could be as-
sayed in the same well. The primers were synthesized by
MWG Biotech (High Point, NC), and the probes were syn-
thesized by Applied Biosystems (ABI, Foster City, CA).
PCR reactions were performed on either the ABI Prism
7000 or ABI Prism 7300. Each reaction consisted of pfmdr1
probe (150 nmol/L), pfmdr1 primers (300 nmol/L), -tubulin
probe (100 nmol/L), -tubulin primers (100 nmol/L), Abgene
QPCR Mastermix (1×), DNA (2 L), and water up to 25 L.
If amplification of a sample was unsuccessful (no amplifica-
tion, replicates being > 50% different, or a copy number
< 0.6), it was repeated with 4 L DNA. The reaction condi-
tions consisted of 95°C for 15 minutes and then 50 cycles of
95°C for 15 seconds and 60°C for 1 minute. The cycle thresh-
old (CT) was calculated with SDS software (ABI). DNA from
strains 3D7 and Dd2 were included on each plate. The 3D7
DNA was extracted from a laboratory grown culture and Dd2
DNA was acquired from MR4 (MRA-387; ATCC, Manassas,
VA).
Pfmdr1 copy number was calculated according to the fol-
lowing formula: copy number  (Etubulin)
CT(tubulin)/
(Epfmdr1)
CT(pfmdr1). The efficiency (E) of -tubulin, which was
higher than that of pfmdr1, was assumed to be 2. Pfmdr1’s
efficiency, relative to that of -tubulin, was calculated for
each plate by assuming the 3D7 control has one pfmdr1 copy.
Dd2, an additional control, was previously determined to
have approximately four pfmdr1 copies.22,23 In our assay,
Dd2 had a mean copy number of 4.27 and a coefficient of
variation of 5.77%.
Statistical analysis. The clinical data were entered into Ex-
cel (Microsoft, Redman, WA) and analyzed with Stata 8.2
(StataCorp., College Station, TX). The clinical outcome of
each patient was classified according to the WHO protocol.17
Because there were no early treatment failures, the main out-
come for this analysis was the recurrence of P. falciparum
parasites in the peripheral blood. Recurrences of parasitemia
were further categorized as reinfections or recrudescence by
the msp1, msp2, and glurp genotyping.
The copy number of samples taken before treatment and
those taken at recurrence were compared using the Wilcoxon
signed rank test.
The relationship between molecular changes in pfmdr1 and
treatment failure was estimated using survival analysis. Be-
cause the subjects were assessed at distinct time-points, the
failure time is interval-censored. Discrete Cox proportional
hazards model was used to take this censoring in account.
This model was estimated using regression with a comple-
mentary log-log link.24 Indicator variables representing four
time periods (0–21, 22–28, 29–35, and 36–42 days) were in-
cluded, whereas a constant term was not estimated. All vari-
ables were assessed for the proportional hazard assumption.
The main outcome was time to recrudescence. Subjects who
were lost to follow-up were censored on their last visit. Sub-
jects who developed a P. vivax infection or a P. falciparum
reinfection were censored on the day of that second diagnosis.
The precision of all hazard ratio estimates were evaluated by
calculating the confidence limits ratio (CLR).25
The genotype at codons 86, 184, 1,034, and 1,042 in pfmdr1
were combined into haplotypes, as previously described.11
The comparison between haplotypes I and III was made be-
cause these haplotypes had the largest sample size and be-
cause a previous in vitro study in Cambodia found haplotype
III was associated with mefloquine resistance and haplotype I
with mefloquine sensitivity.9 Samples that were a mixture of
haplotypes I and III were coded as haplotype III. The rela-
tionship between copy number and time to recrudescence was
not linear on the log hazard scale. Therefore, copy number
was coded as a binary variable of less than three copies and at
least three copies to reflect the relationship between copy
number and time to recrudescence and to meet the propor-
tional hazards assumption of the model.
The following covariates were evaluated as potential effect
measure modifiers and confounders: previous use of antima-
larials, initial parasite density, age, sex, and hematocrit. Initial
parasite density was coded as a binary variable, with the cut-
off point of 80,000 parasites/L. Effect measure modification
was assessed with the Wald test for the interaction term in the
model (P  0.1 was considered significant). All non-effect
measure modifiers were evaluated in a directed acyclic dia-
gram to select a sufficient set of covariates to control for
confounding.26
The population attributable rate fraction (AFp) and 95%
confidence intervals (CIs) were calculated.27 The specific for-
mula for AFp was [(HRadj – 1) × p)/HRadj, where HRadj 
adjusted hazard ratio, and p  proportion of cases that were
exposed.
The relationship between molecular change in pfmdr1 and
parasite clearance time was assessed using discrete Cox pro-
portional hazards model in the same manner as described
above.
Ethics. Informed consent was obtained from all adult sub-
jects and from the parent or guardian of all minors. The
pfmdr1 genotyping and data analysis were approved by the
Institutional Review Boards at the United States Naval Medi-
cal Research Unit No. 2 and at UNC Chapel Hill School of
Public Health. Both the genotyping and the efficacy study was
approved by the National Ethics Committee for Health Re-
search, Ministry of Health, Cambodia.
RESULTS
Efficacy study. Of the 81 people enrolled, 10 were lost to
follow-up, 7 were diagnosed with P. vivax, and 25 people
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experienced late treatment failure between Days 14 and 42
(Figure 1). msp1, msp2, and glurp genotyping determined that
13 of the 25 recurrences were caused by recrudescence of the
original infection. In the enrollment samples, there were two
msp1 variants, five msp2 variants, and five glurp variants. The
prevalence of the most common msp1/msp2/glurp haplotype
was 8%, which implies there is a low probability of a reinfec-
tion having an identical haplotype to the original infection.
Enrollment samples were available for pfmdr1 genotyping
for all but one subject. This subject was a child who recru-
desced on Day 14. Clinical and demographic information for
the remaining 80 subjects are presented in Table 1.
Genotyping of enrollment samples. Of the 80 enrollment
samples, 75 (93.8%) were successfully genotyped at all four
pfmdr1 codons. Of the remaining five samples, genotyping of
one sample was unsuccessful at pfmdr1–86, one was unsuc-
cessful at pfmdr1–1034, and three were unsuccessful at
pfmdr1–1042. Most samples had either the I or III haplotype
(Table 2). pfmdr1-86-Tyr was not observed.
pfmdr1 copy number was successfully determined for all
enrollment samples. The median copy number was 1.50
(range, 0.60–6.28), and 18.8% contained three or more copies.
Elevated copy number was only observed in the presence of
86-Asn, 1034-Ser, and 1042-Asn (haplotypes I and III). There
was no association between copy number and pfmdr1-184
genotype (ANOVA, F  0.51, P  0.479).
Comparison of enrollment and recurrence pfmdr1 geno-
types. pfmdr1 copy number was determined for all recrudes-
cent (N  12) and all reinfection (N  12) samples; 75.0%
(9/12) of the reinfection samples and 66.7% (8/12) of the
recrudescent samples had a higher copy number than the cor-
responding enrollment sample. These differences were not
statistically significant (Wilcoxon signed rank test, for recru-
descent: z  1.26, P  0.209; for reinfection: z  1.57, P 
0.117). However, when comparing all enrollment and recur-
rent samples, the difference was statistically significant (Wil-
coxon signed rank test, z  2.06, P  0.040). Therefore,
artesunate-mefloquine treatment seems to select for in-
creased pfmdr1 copy number.
Four recrudescent and 10 reinfection samples were geno-
typed for pfmdr1 polymorphisms. When comparing the hap-
lotypes at enrollment and recurrence for the reinfection
samples, five were identical, one sample changed from hap-
lotype IV to III, two samples changed from being mixed (hap-
lotypes I and III) to haplotype III, and two samples changed
from having haplotype III to being mixed (haplotypes I and
III). The four recrudescent samples had identical haplotypes
to the enrollment sample (three of these paired samples had
haplotype III and one had haplotype I). Thus, there seems to
be no selection of a particular pfmdr1 haplotype because of
artesunate-mefloquine treatment.
pfmdr1 and time to recrudescence. Subjects with increased
pfmdr1 copy number recrudesced sooner and more often than
subjects with low copy number (Figure 2; Table 3). The crude
hazard ratio for increased copy number (at least three copies
compared with less than three copies) on time to recrudes-
cence was 8.30 (95% CI: 2.60–26.43). Adjusting for confound-
ers resulted in a hazard ratio of 7.91 (95% CI: 2.38–26.29).
These results were not dependent on the statistical model,
because the hazard ratio from a continuous Cox proportional
model was similar in size and precision. Thus, pfmdr1 copy
number is strongly related to time to recrudescence.
For pfmdr1 haplotype, 11 of 12 recrudescences occurred in
subjects infected with parasites with haplotypes I and III. One
subject with parasites with an incomplete haplotype also re-
crudesced. None of the four subjects with parasites with hap-
lotype IV recrudesced; however, the small sample size pre-
vents further evaluation of this haplotype. The crude hazard
ratio of time to recrudescence comparing haplotype III to I
was 2.22 (95% CI: 0.28–17.34). Adjusting for confounders
resulted in a slightly lower hazard ratio (1.88; 95% CI: 0.24–
15.00). There seems to be little difference between haplotype
III and I on time to recrudescence; however, the estimate is
very imprecise (CLR  61.36).
To investigate the impact of increased pfmdr1 copies on
recrudescence in the entire cohort, the population attribut-
FIGURE 1. Flowchart describing the results of the in vivo efficacy
trial in 2004 in Pailin, Cambodia.
TABLE 1
Clinical characteristics of the subjects in the Pailin in vivo efficacy
study that were genotyped for pfmdr1
Characteristic Number
Men (%) 57 (71.3%)
Median age (range) 20 (6–65)
Geometric mean parasite density
[parasites/L (SD)] 1.89 × 104 (1.16 × 105)
Mean hematocrit (SD) 38.7 (5.3)
Previous use of antimalarials* (%) 28 (37.8%)
Sample size is 80, unless otherwise specified.
* In the past month by self-report (n  74).
TABLE 2
pfmdr1 haplotypes of samples taken at enrollment with successful
genotyping at all codons
86 184 1034 1042 Haplotype Number
Asn Tyr Ser Asn I 13
Asn Phe Ser Asn III 57†
Asn Phe Ser Asp IV 4‡
Asn Tyr Cys Asn V 1
Amino acids representing the mutant genotype are in bold.
* From reference 11.
† Five samples were mixed at 184.
‡ One sample was mixed at 1,042.
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able fraction was calculated. Using the prevalence of greater
than three pfmdr1 copies in the cases (58.3%) and the ad-
justed hazard ratio (7.91), the population attributable fraction
of recrudescence for increased pfmdr1 copy number was
50.9% (95% CI: 4.1–74.9%). pfmdr1 copy number seems to
contribute to the cause of one half the cases of recrudescence
observed in this study.
When the outcome of all recurrences of parasites (recru-
descence + reinfection) was used, the estimate of effect for
copy number was lower (unadjusted HR  4.51, 95% CI:
1.99–10.23; adjusted HR  4.02, 95% CI: 1.73–9.34). In con-
trast, the hazard ratio for time to recurrence for haplotype III
was higher but very imprecise (unadjusted HR  4.78, 95%
CI: 0.64–35.64; adjusted HR  4.40, 95% CI: 0.59–33.02).
Therefore, the estimated effect of pfmdr1 haplotype but not
copy number changes depending on whether the treatment
failures were PCR corrected. This suggests that if some mis-
classification of recrudescence and reinfection had occurred,
the interpretation of the effects would not be substantially
different.
The pfmdr1 copy number is a potential screening tool for
drug resistance. Having parasites with greater than three
pfmdr1 copies before treatment identified cases of recrudes-
cence with a sensitivity and specificity of 58.3% and 88.2%,
respectively, and a positive predictive value of 66.7%. Includ-
ing information on either pfmdr1 haplotype or initial parasite
density increased the specificity but decreased the sensitivity
of predicting recrudescence (at least three copies + haplotype
III: sensitivity  50.0%, specificity  91.2%; at least three
copies + parasitemia  80,000: sensitivity  50.0%, specificity
 91.2%).
pfmdr1 and parasite clearance time. Of the 80 subjects, 4
(5.0%) cleared the parasitemia by Day 1, 41 (51.3%) cleared
by Day 2, 27 (33.8%) cleared by Day 3, and 8 (10.0%) cleared
by Day 4. The parasite clearance times observed in this study
are longer than reported previously for artesunate-meflo-
quine.28
Increased copy number was not associated with delayed
parasite clearance when controlling for parasite density and
hematocrit (Table 4). There was a slight association between
pfmdr1 haplotype and delayed parasite clearance time, al-
though the estimate was imprecise.
DISCUSSION
In this study, pfmdr1 copy number at the time of treatment
initiation was strongly associated with recrudescence after
TABLE 3






Crude hazard ratio Adjusted† hazard ratio
HR CI CLR* HR CI CLR
Copy number < 3 65 5 1.‡ 1.
 3 15 7 8.30 2.60–26.43 10.17 7.91 2.38–26.29 11.04
Haplotype I 13 1 1. 1.
III 57 10 2.22 0.28–17.34 61.93 1.88 0.24–15.00 62.50
Hematocrit < 40 39 7 1.
 40 41 5 0.68 0.22–2.15 9.78
Parasite density < 80,000 58 6 1.
 80,000 22 6 3.09 1.00–9.61 9.61
* Confidence limit ratio  upper limit/lower limit.
† Adjusted for initial parasite density and hematocrit.
‡ Referent level.
FIGURE 2. The percentage of subjects who have not recrudesced after artesunate-mefloquine treatment by A, pfmdr1 copy number and B,
pfmdr1 haplotype. In B, only samples with haplotypes I, III, and IV were included. The haplotypes are defined in Table 2.
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artesunate-mefloquine administration. After adjusting for
confounding, subjects infected with parasites having greater
than three copies of pfmdr1 had 7.91 times the risk of recru-
descence as subjects harboring parasites with less than three
copies. pfmdr1 copy number was an important determinant of
recrudescence, as shown by the population attributable frac-
tion of 50.9%. In addition, artesunate-mefloquine treatment
was found to select for increased pfmdr1 copy number, be-
cause parasites from recurrent infections had significantly
higher copy numbers than parasites from those same patients
on enrollment. These data show that artesunate-mefloquine
failures are associated with a specific drug-resistance biomar-
ker and that treatment may increase the prevalence of this
biomarker in the general population.
Our observed association between pfmdr1 and failure is
consistent with previous in vivo studies that looked at meflo-
quine monotherapy and artesunate-mefloquine combination
therapy.13,21 In both studies, associations between pfmdr1
copy number and drug failure were found, but no association
was seen between pfmdr1 haplotype and drug failure. In con-
trast, numerous in vitro studies have found associations be-
tween both copy number and haplotype and in vitro
IC50.
13,21,29–31 There are four possible reasons for this. First,
the effect of these mutations might be too small to be seen in
vivo. Second, determinations of SNPs in complex polyclonal
infections could result in misclassification. Third, in Pailin, the
pfmdr1 genotype had minimal variation, with some sensitive
genotypes being either rare or absent, so the effect might have
been missed. Last, the factors responsible for resistance might
differ by geographic region. Therefore, the inconsistency of
results could be caused by the fact that several of the in vitro
studies were executed outside of Southeast Asia.
It has been suggested that increased pfmdr1 copy number
might cause resistance to both artesunate and meflo-
quine.11–13,16 The observed drug failures are probably caused
by mefloquine resistance, because a study in Pailin in 2001–
2002 found the clinical isolates had high mefloquine IC50s and
low artesunate IC50s.
32 Also, parasite clearance is predomi-
nantly caused by artesunate, and no effect of pfmdr1 copy
number on parasite clearance time was observed in this study.
Therefore, the effect pfmdr1 copy number on recrudescence
is most likely caused by the effect of pfmdr1 on mefloquine
sensitivity and not artesunate sensitivity.21
We observed an increase in pfmdr1 copy number in para-
sites isolated after artesunate-mefloquine treatment. Because
mefloquine has a much longer half-life than artesunate (14–41
days versus 1 hour),33,34 resistant parasites were probably se-
lected by exposure to subtherapeutic concentrations of the
single drug mefloquine.35 Selection for mefloquine resistance
in Pailin may have also been facilitated by the pre-existence
of resistance to this drug.36,37 This observation suggests that
ACT selects for resistance to the non-artemisinin partner
drug.
Strengths of this study include the fact that genotyping was
done directly on peripheral blood samples, which negates the
potential bias caused by culturing.20 Another strength is its
42-day follow-up with PCR correction.38 The main limitation
of this study is the small sample size, which affected the power
and the precision of the effect estimates, especially for pfmdr1
haplotypes. Another limitation is that not all predictors of
recrudescence were measured, such as pharmacokinetics, host
genetics, immunity, and nutritional status.
Molecular markers of drug-resistant malaria, such as
pfmdr1, are promising tools for the surveillance of drug re-
sistance. pfmdr1 copy number is not only strongly associated
with recrudescence to artesunate-mefloquine but also with
Coartem failure (artemether-lumefantrine).39 Surveillance
for increased pfmdr1 copy number could aid malaria control
efforts by pinpointing areas where these drugs may be failing.
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